



GP1646

Approved 00270 PTO/SB/21 (08-00)
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

<h1>TRANSMITTAL FORM</h1> <p><i>(to be used for all correspondence after initial filing)</i></p>	Application Number	10/079,068	
	Filing Date	02/20/2002	
	First Named Inventor	Giorgio Trinchieri et al	
	Group Art Unit	1646	
	Examiner Name	S. Prasad	
Total Number of Pages in This Submission		8	
		Attorney Docket Number	WST85BUSA


ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below)
<div style="text-align: right;"> <p>RECEIVED</p> <p>MAY 01</p> <p>TECH CENTER 1000</p> </div>		
<div style="border: 1px solid black; padding: 5px;"> Remarks </div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Mary E. Bak, Esquire Howson and Howson
Signature	<i>Mary E. Bak</i>
Date	<i>April 18 2002</i>

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date			
			04/18/2002
Typed or printed name	Debra N. Gerstemeier		
Signature	<i>Debra N. Gerstemeier</i>	Date	<i>4-18-2002</i>

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary, depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

COPY OF PAPERS
ORIGINALLY FILED



00270

PATENT TRADEMARK OFFICE

WST85BUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of) Group Art Unit 1646
)
Giorgio Trinchieri et al) Examiner S Prasad
)
Appln No 10 079,068)
)
Filed February 20, 2002)
)
For METHODS AND COMPOSITIONS FOR) April 18, 2002
ENHANCING THE IMMUNO-)
STIMULATORY EFFECT OF)
INTERLEUKIN-12)

RECEIVED

MAY 01 2002

TECH CENTER 600 2900

Commissioner for Patents
U S Patent and Trademark Office
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir

Applicants submit to the Examiner the attached Form PTO SB 08A B document listing and this paper pursuant to 37 CFR §1.56 and § 1.97-1.98 Form PTOSB 08A B and this paper identify documents previously cited in the parent application, U S Patent Application No 09 395,038, filed September 13, 1999, which is currently pending

CERTIFICATE UNDER 37 CFR 1.58a

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231, on April 18, 2002.

Signature

Typed or printed name

Debra N Gerstemeier

According to 37 CFR § 1.98(d), Applicants have not enclosed copies of any U.S. patents, publications or other documents listed herein, which listed items were previously cited by or submitted to the United States Patent and Trademark Office in parent U.S. Patent Application No. 09/395,038, filed September 13, 1999 (pending). The parent patent application is relied upon herein for an earlier priority date under 35 USC §120.

This Information Disclosure Statement is submitted within three months of the filing date of this application, and prior to receipt of an Office Action on the merits. Therefore, no fees are believed due. However, the Director of the U.S. Patent and Trademark Office is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees paid on the filing, or during prosecution of this application to Deposit Account No. 08-3040.

The Examiner is respectfully requested to consider the documents identified in this paper and in the attached Form PTO SB/08A/B during the course of the examination of this application.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for the Applicants

By

Mary E. Bak
Mary E. Bak
Registration No. 31,215
Spring House Corporate Center
Box 457
Spring House, PA 19477
Telephone (215) 540-9206
Telefacsimile (215) 540-5818

Please type a plus sign (+) inside this box ☐

APR 29 2002

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known			
				Application Number	10 079,068		
				Filing Date	February 20, 2002		
				First Named Inventor	Giorgio Trinchieri et al		
				Group Art Unit	1646		
				Examiner Name	S Prasad		
Sheet	1	2	3	4	5	Attorney Docket Number	WST85BU5A

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ²	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ³ (if known)			
	AA	5,457,038	B1	G Trinchieri	10/10/1995	RECEIVED MAY 01 2002 TECH CENTER 1600-2800
	AB	5,571,515	B1	P Scott	11/05/1996	
	AC	5,723,127	B1	P Scott	03/03/1998	
	AD	5,976,539	B1	P Scott	11/02/1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ²	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	1*
		Office	Number ⁴	Kind Code ³ (if known)				
	AL	WO	WO90 05147	A1	G Trinchieri	05/17/1990		
	AM	WO	WO94 01139	A1	F Ledley	01/20/1994		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER Initial reference considered whether or not citation is in conformance with MPEP 2112. Draw line thru citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Indicate citation designation number. See attached Kinds 1-11. ² U.S. Patent Documents: Enter Office that issued the document, by the two-letter code (WIPO Standard S1.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbol as indicated in the document under WIPO Standard S4.1. ⁵ If possible, Applicant is to place a check mark here if English language translation is attached.

COPY OF PAPERS
ORIGINALLY FILED

Please type a plus sign (+) inside this box ☐

OTPE
APR 29 2002
PATENT & TRADEMARK

PLOSB/NO. 8000

Substantiated Form 144-A PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10 079,068
				Filing Date	February 20, 2002
				First Named Inventor	Giorgio Trinchieri
				Group Art Unit	1646
Examiner Name				S. Prasad	
Sheet	2	of	5	Attorney Docket Number	
				WST85BU5A	

RECEIVED
MAY 01 2002
JEO CENTER 800-2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiners Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS); title of the article (when appropriate); title of the item (book, magazine, journal, serial, symposium, catalog, etc.); date; page(s); volume-issue number(s); publisher, city and/or country where published	12
	AR	E VOEST et al. "Inhibition of Angiogenesis in Vivo by Interleukin 12", J Natl Cancer Inst, 87 5813 (April 19, 1995)	
	AS	A D'ANDREA et al. "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells", J Exp Med, 176 1387 (November, 1992)	
	AT	G TRINCHIERI, "Interleukin-12: A Proinflammatory Cytokine with Immunoregulatory Function that Bridge Innate Resistance and Antigen-Specific Adaptive Immunity", Annu Rev Immunol, 13 251 (1995)	
	AU	M BRUNDA, "Role of IL-12 as an Anti-tumour Agent: Current Status and Future Directions", Res Immun, 146 622 (September-October, 1995)	
	AV	R GAZZINELLI et al. "Interleukin-12 is Required for the T-lymphocyte-Independent Induction of Interferon γ by an Intracellular Parasite and Induces Resistance in T-cell-deficient Hosts", Proc Natl Acad Sci USA, 90 6115 (July, 1993)	
	AW	G MULLER et al. "IL-12 as Mediator and Adjuvant for the Induction of Contact Sensitivity in Vivo", J Immunol, 155 4661 (November 15, 1995)	
	AX	C SGADARI et al. "Inhibition of Angiogenesis by Interleukin-12 is Mediated by the Interferon-Inducible Protein 10", Blood, 87 3877 (May 1, 1996)	
	AY	F HEINZEL et al. "Recombinant Interleukin 12 Cures Mice Infected with Leishmania Major", J Exp Med, 177 1505 (May, 1993)	
	AZ	C COUGHLIN et al. "The Effect of Interleukin 12 Desensitization on the Antitumor Efficacy of Recombinant Interleukin 12", Cancer Res, 57 2460 (June 15, 1997)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER Initial if reference considered (whether or not citation is in conformance with MPEP). Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. *Applicant(s) place a check mark here if English language translation is attached.

COPY OF PAPERS
ORIGINALLY FILED

Please type a plus sign (+) inside this box ☐

APR 29 2002
O I P E
PATENT & TRADEMARK

PLEASE PRINT

Substituted Form 144-A PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Use as many sheets as necessary.				Complete if Known	
				Application Number	10 079,068
				Filing Date	February 20, 2002
				First Named Inventor	Giorgio Trinchieri
				Group Art Unit	1646
				Examiner Name	S. Prasad
Sheet	3	of	5	Attorney Docket Number	WST85BUSA

RECEIVED
MAY 01 2002
TEC-CENTER 1600:2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiners Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	11
	AAR	J. ORANGE et al., "Effects of IL-12 on the Response and Susceptibility to Experimental Viral Infections", J. Immunol., 152:1253 (February 1, 1994)	
	AAS	J. COHEN, "IL-12 Deaths: Explanation and a Puzzle", Science, 270:908 (November 10, 1995)	
	AAT	C. COUGHLIN et al., "Interleukin-12 and Interleukin-18 Synergistically Induce Murine Tumor Regression which Involves Inhibition of Angiogenesis", J. Clin. Invest., 101:1441 (March 15, 1998)	
	AAU	M. ATKINS et al., "Phase I Evaluation of Intravenous Recombinant Human Interleukin 12 in Patients with Advanced Malignancies", Clin. Cancer Res., 3:409 (March, 1997)	
	AAV	H. KURZAWA et al., "Recombinant Interleukin-12 Enhances Cellular Immune Responses to Vaccination only after a Period of Suppression", Cancer Res., 58:491 (February 1, 1998)	
	AAW	Y. NOGUCHI et al., "Influence of Interleukin 12 on p53 Peptide Vaccination Against Established Meth A Sarcoma", Proc. Natl. Acad. Sci. USA, 92:2219 (March, 1995)	
	AAX	M. KOBAYASHI et al., "Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), a Cytokine with Multiple Biologic Effects on Human Lymphocytes", J. Exp. Med., 170:827-845 (September, 1989)	
	AAZ	C. HUNTER et al., "Studies on the Role of Interleukin-12 in Acute Murine Toxoplasmosis", Immunol., 84:16 (January, 1995)	


Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP § 9. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Unique citation designation number: * Applicant is to place a check mark here if English language translation is attached.

COPY OF PAPERS
ORIGINALLY FILED

Please type a plus sign (+) inside this box ☐



P105B (Rev. 8-97)

Substituted Form 1449 (P10) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if known	
				Application Number	10 079,068
				Filing Date	February 20, 2002
				First Named Inventor	Giorgio Trinchieri et al
				Group Art Unit	1646
				Examiner Name	S. Prasad
Sheet	4	of	5	Attorney Docket Number	WST85BUSA

RECEIVED

MAY 01 2002

TECH CENTER 1600/29

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	P ²
	AAZ	S. GREGORY et al, "Reactive Nitrogen Intermediates Suppress the Primary Immunologic Response to Listeria", J. Immunol., 150 2901 (April 1, 1993)	
	BR	M. SCHWACHA et al, "Interleukin-12 is Critical for Induction of Nitric Oxide-Mediated Immunosuppression Following Vaccination of Mice with Attenuated Salmonella typhimurium", Infection and Immunity, 65 4897 (December, 1997)	
	BS	R. FERNANDEZ-GOMEZ et al, "Trypanosoma cruzi Tc52 Released Protein-Induced Increased Expression of Nitric Oxide Synthase and Nitric Oxide Production by Macrophages", J. Immunol., 160 3471 (April 1, 1998)	
	BT	E. CANDOLFI et al, "Mitogen- and Antigen-Specific Proliferation of T Cells in Murine Toxoplasmosis is Inhibited by Reactive Nitrogen Intermediates", Infection and Immunity, 62 1995 (May, 1994)	
	BU	K. FECHO et al, "Macrophage-Derived Nitric Oxide is Involved in the Depressed Concanavalin A Responsiveness of Splenic Lymphocytes from Rats Administered Morphine in Vivo", J. Immunol., 152 5845 (June 15, 1994)	
	BV	J. MACMICKING et al, "Nitric Oxide and Macrophage Function", Annu. Rev. Immunol., 15 323 (1997)	
	BW	A. KOMAROV et al, "Iron Potentiates Nitric Oxide Scavenging by Dithiocarbamates in Tissue of Septic Shock Mice", Biochim. Biophys. Acta, 1361(3) 229-234 (October 24, 1997)	
	BX	M. IKEDA et al, "Nitric Oxide Inhibits Intracellular Adhesion Molecule-1 Expression in Rat Mesangial Cells", J. Am. Soc. Nephrol., 7(10) 2213-2218 (October, 1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: If the reference is considered whether or not it contains new information with MPPI P-10, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language translation is attached.

COPY OF PAPERS
ORIGINALLY FILED

Please type a plus sign (+) inside this box ☐

APR 29 2002

PLEASE PRINT

Substantive Form 144 XPLO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Use as many sheets as necessary				Complete if known	
				Application Number	10 079,068
				Filing Date	February 20, 2002
				First Named Inventor	Giorgio Trinchieri et al
				Group Art Unit	1646
				Examiner Name	S. Prasad
Sheet	5	of	5	Attorney Docket Number	WST85BUSA

RECEIVED
MAY 01 2002
TECH CENTER 18002

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	12
	BY	A. HUGHES et al, "Effect of Reactive Oxygen Species on Endothelin-1 Production by Human Mesangial Cells", Kidney Int., 49(1) 181-189 (January, 1996)	
	BZ	G. TRINCHIERI, "Interleukin-12: A Cytokine by Antigen-Presenting Cells with Immunoregulatory Functions in the Generation of T-Helper Cells Type 1 and Cytotoxic Lymphocytes", Blood, 84 4008 (December 15, 1994)	
	BBR	F. LIEW et al, "Cytokines and Nitric Oxide as Effector Molecules Against Parasitic Infections", Phil Trans R Soc Lond B, 352 1311-1315 (1997)	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER Initial: if reference considered, whether or not citation is in conformance with MPEP § 900. Draw line through citation if not in conformance and not considered. (Include copy of this form with next communication to applicant.)

12 Unique citation designation number. Applicant to place a check mark here if English language translation is attached.

COPY OF PAPERS
ORIGINALLY FILED